Daily Cosmetic Research Analysis
Three studies stand out today at the interface of cosmetic outcomes and clinical innovation: a prospective multicenter cohort shows methyl aminolevulinate artificial daylight photodynamic therapy (MAL-aDL-PDT) improves photoaging metrics while treating actinic keratoses; a first-in-human trial protocol evaluates intraoperative non-thermal plasma after breast-conserving surgery with cosmetic endpoints; and a surgical series introduces a zygomatic-branch–guided retrograde approach for parotidectom
Summary
Three studies stand out today at the interface of cosmetic outcomes and clinical innovation: a prospective multicenter cohort shows methyl aminolevulinate artificial daylight photodynamic therapy (MAL-aDL-PDT) improves photoaging metrics while treating actinic keratoses; a first-in-human trial protocol evaluates intraoperative non-thermal plasma after breast-conserving surgery with cosmetic endpoints; and a surgical series introduces a zygomatic-branch–guided retrograde approach for parotidectomy that shortens operative time and reduces bleeding with cosmetically favorable scars.
Research Themes
- Dermatologic photodynamic therapy with cosmetic benefits
- Intraoperative non-thermal plasma as an oncologic adjunct with cosmesis assessment
- Head and neck surgical approaches optimizing efficiency and esthetic outcomes
Selected Articles
1. Photoaging and Cosmetic Result with Artificial Daylight Photo-dynamic Therapy Using Methyl Aminolevulinate.
In a prospective multicenter real-world cohort (n=224), MAL-aDL-PDT for facial/scalp actinic keratoses significantly improved five photoaging parameters at 3 months (all p<0.001). Patients (81.3%) and investigators (83.6%) rated cosmetic outcomes as good/very good, indicating field treatment benefits beyond lesion clearance.
Impact: This real-world prospective study provides quantitative evidence that MAL-aDL-PDT delivers cosmetic benefits in addition to treating actinic keratoses, directly informing patient counseling and modality selection.
Clinical Implications: Clinicians can position MAL-aDL-PDT as a dual-purpose field therapy for AKs that also improves photoaging features, setting expectations for smoother texture, reduced mottling, telangiectasia, and fine lines within 3 months.
Key Findings
- All five photoaging parameters significantly decreased at month 3 versus baseline (p<0.001).
- Cosmetic outcome rated good/very good by 81.3% of patients and 83.6% of investigators.
- Field-directed MAL-aDL-PDT improved tactile roughness, mottled pigmentation, telangiectasias, and fine lines.
- Consistent cosmetic benefits observed across different artificial daylight systems under real-world conditions.
Methodological Strengths
- Prospective, multicenter, non-interventional design with standardized photoaging scoring.
- Adequate sample size (n=224) and real-world use of multiple artificial daylight systems.
Limitations
- No randomized control group; potential placebo or observer bias.
- Short follow-up (3 months) and predominantly male, single-country cohort.
Future Directions: Conduct randomized controlled trials comparing aDL-PDT with standard PDT or alternative field therapies on cosmetic and oncologic endpoints with longer follow-up and diverse populations.
Artificial daylight photodynamic therapy with methyl aminolevulinate is an effective and almost painless treatment approach for actinic keratoses. The objective of the prospective, non-interventional, multicentre study ArtLight (NCT05725213) was to gain comprehensive insights into the cosmetic effect of methyl aminolevulinate-artificial daylight photodynamic therapy in patients with actinic keratoses using different artificial daylight systems under real-world conditions. The study enrolled patients with Olsen grade 1 or 2 actinic keratoses on the face and scalp in Germany. Patients were treated with methyl aminolevulinate-artificial daylight photodynamic therapy. The cosmetic effect was assessed via photodamage parameters (global score for photoaging, mottled pigmentation, tactile roughness, telangiectasias, fine lines). Each photodamage variable was recorded on a 5-point scale (0-4). In total, 224 patients (median age: 75.0 years [range 50-91], 85.3% male, 62.5% Olsen grade 2, 55.4% treatment-naive) were treated with methyl aminolevulinate-artificial daylight photodynamic therapy. At month 3, all 5 parameters of photoaging were significantly reduced from baseline (p < 0.001). The majority of patients (81.3%) and investigators (83.6%) rated the cosmetic result as good or very good. Beyond effective eradication of actinic keratoses, field-directed methyl aminolevulinate-artificial daylight photodynamic therapy can improve photoaging symptoms, including tactile roughness, mottled pigmentation, telangiectasis, and fine lines. Thus methyl aminolevulinate-artificial daylight photodynamic therapy provides additional benefits, particularly for patients concerned with cosmetic outcomes during or after treatment.
2. Breast cancer PAINT: a first-in-human, dose-escalation study to determine the safety of Plasma Adjuvant INtra-operative Treatment in breast cancer patients.
This first-in-human, single-arm 3+3 dose-escalation trial will assess the safety and tolerability of intraoperative non-thermal plasma applied to the tumor bed after lumpectomy, with up to 3-month follow-up. Secondary endpoints include cosmetic assessments and tissue analyses; the trial is registered (NCT06222788).
Impact: It introduces an innovative intraoperative adjuvant with potential to reduce local recurrence after breast-conserving surgery while prospectively incorporating cosmetic outcomes.
Clinical Implications: If found safe and feasible, intraoperative non-thermal plasma could be integrated into breast-conserving workflows as a localized adjuvant; early cosmetic monitoring supports patient-centered decision-making.
Key Findings
- First clinical trial to assess non-thermal plasma in an all–breast cancer cohort undergoing lumpectomy.
- Three groups (A ex vivo, B in situ excised, C in situ retained) with 3+3 dose escalation up to level 3.
- Safety monitored via dose-limiting toxicity and AEs coded by CTCAE v5.0; follow-up up to 3 months.
- Cosmetic outcomes assessed by patient-reported QoL (appearance/texture) and standardized photography; registered as NCT06222788.
Methodological Strengths
- Prospective 3+3 dose-escalation design with predefined dose-limiting toxicity criteria and CTCAE v5.0 coding.
- Trial preregistration and integration of cosmetic endpoints and translational tissue analyses.
Limitations
- Single-arm phase I design without efficacy endpoints; small planned sample and short follow-up.
- Single-center study limits generalizability; cosmetic assessments may be subject to reporting bias.
Future Directions: If safety is confirmed, proceed to phase II/III trials testing local recurrence reduction and cosmetic outcomes, and optimize NTP parameters and delivery tools.
BACKGROUND: Non-thermal plasma (NTP) refers to an ionized gas composed of ions, electrons and other reactive agents. The anticancer properties of NTP have been proven in vitro and in vivo. The 10-year local recurrence risk (LRR) in breast cancer patients after breast conservation therapy (i.e., lumpectomy, typically followed by radiation therapy) is still as high as 15-20%. NTP could be used to further treat the tumor bed to reduce the LRR. METHODS: Our primary objective is to determine the safe and tolerable dose of NTP treatment following breast cancer lumpectomy. Our secondary objectives are to assess the safety and tolerability of NTP and to assess the cosmetic effects of NTP treatment in patients with breast cancer. Our exploratory objective is to assess the impact of NTP treatment on cancerous and normal tissues. Patients are followed for up to 3 months after NTP treatment. The patients are divided into 3 groups: group A (n = 3): NTP treatment of part of the tumor bed ex vivo. Group B (n = 3): NTP treatment of part of the tumor bed in situ (all treated tissues are removed for analysis). Group C (n = 6-24): dose escalation per "3 + 3 Design" up to a maximum dose level of 3. NTP treatment of part of the tumor bed in situ (the treated parts of the tumor bed will not be excised, except for a small portion for analysis). DISCUSSION: The safety and tolerability of treatment will be evaluated by means of dose-limiting toxicity, adverse event (AE) and serious adverse event reports; physical examinations; and laboratory safety evaluations. AEs will be coded according to CTCAE v5.0. The results will be tabulated to examine their frequency, grade, and relationship to the study treatment. The results of laboratory assessments will be evaluated similarly. The number of patients with cosmetic alterations linked to NTP treatment and the type of alteration will be assessed through quality of life questionnaires (questions about breast appearance and texture) and through photo collection. This is the first clinical trial to study the safety and tolerability of NTP in an all-breast cancer patient cohort. TRIAL REGISTRATION: Name of the registry: ClinicalTrials.gov. TRIAL REGISTRATION NUMBER: NCT06222788. Date of registration: 01/15/2024. URL of trial registry record: https://clinicaltrials.gov/study/NCT06222788 .
3. Comparison of surgical outcomes between anterograde and retrograde approaches for partial superficial parotidectomy in pleomorphic adenoma: A new surgical technique of the retrograde approach guided by the zygomatic branch.
In 241 cases of pleomorphic adenoma, the retrograde approach (RA) achieved shorter operative time (64.0 vs 94.6 min) and less bleeding (11.4 vs 43.8 mL) than the anterograde approach (AA). The novel zygomatic-branch–guided RA via preauricular incision was most efficient (53.8 min) with the least bleeding (6.8 mL) and cosmetically satisfactory scars.
Impact: The study introduces a zygomatic-branch–guided retrograde technique with clear indications that improves efficiency and cosmetic outcomes compared with traditional approaches.
Clinical Implications: For anterior or tail parotid lesions, surgeons can preferentially select retrograde approaches—especially zygomatic-branch–guided RA—to minimize visible scarring, reduce bleeding, and shorten operative time while maintaining low complications.
Key Findings
- RA had shorter mean operative time than AA (64.0 vs 94.6 min).
- RA had lower mean bleeding volume than AA (11.4 vs 43.8 mL).
- Zygomatic-branch–guided RA showed the shortest time (53.8 min) and least bleeding (6.8 mL).
- Complication rates were low, and scars along cleavage lines or sideburns were cosmetically satisfactory.
Methodological Strengths
- Large single-center cohort (n=241) with clear, anatomy-based selection criteria by tumor location.
- Objective intraoperative metrics (time, blood loss) and attention to scar placement along cleavage lines.
Limitations
- Retrospective, non-randomized design with potential selection bias.
- Follow-up duration and long-term recurrence or facial nerve outcomes were not fully detailed.
Future Directions: Prospective comparative studies with standardized scar assessment scales and long-term facial nerve and recurrence outcomes to validate indications.
OBJECTIVE: Partial superficial parotidectomy is commonly performed for pleomorphic adenoma of the parotid gland. The Blair incision, frequently used for superficial parotidectomy, provides wide surgical exposure but leaves a visible periauricular scar misaligned with facial skin cleavage lines. To enhance esthetics and reduce invasiveness, we use the anterograde approach (AA) with a postauricular incision or the retrograde approach (RA) guided by either the zygomatic branch (ZB) with preauricular incisions or the marginal mandibular branch (MB) with an arc-shaped neck incision, depending on tumor location. Notably, the RA guided by the ZB with preauricular incision is a novel technique. This study presents a new RA technique and defines indications for AA and RA. METHODS: The approach varied depending on tumor location. If the tumor was located in the tail or anterior border of the parotid gland, we selected the RA guided by the marginal MB using an arc-shaped neck incision or the RA guided by the ZB using a preauricular incision within the sideburns, respectively. For other cases, AA using a postauricular incision was selected regardless of the tumor size. RESULTS: Among 241 patients, AA was performed in 195 and RA in 46 patients; MB- and ZB-guided RA were performed in 20 and 26 patients, respectively. The mean operation times for AA and RA were 94.6 and 64.0 min, respectively. The mean operation times for MB- and ZB-guided RA were 77.1 and 53.8 min, respectively. The operation time was significantly shorter in RA than in AA; ZB-guided RA had the shortest operation time in the three groups. The mean bleeding volumes were 43.8 and 11.4 mL in AA and RA cases, respectively. The mean bleeding volumes of MB- and ZB-guided RA were 17.6 and 6.8 mL, respectively. The bleeding volume was significantly less in RA than in AA; ZB-guided RA had the least bleeding volume in the three groups. Complication rates were low, and postoperative incision scars along the postauricular and neck cleavage lines or on sideburns were cosmetically satisfactory. CONCLUSION: In the present study, we reported a novel surgical technique for RA guided by the ZB. The surgical results and postoperative aesthetic outcomes were favorable, supporting the appropriateness of our surgical indications for AA and RA and the utility of RA guided by ZB with a preauricular incision.